These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20425271)

  • 61. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
    Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
    Serban MC; Banach M; Mikhailidis DP
    Expert Opin Pharmacother; 2016; 17(3):369-80. PubMed ID: 26559810
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Management of statin-intolerant high-risk patients.
    Tziomalos K; Athyros VG; Karagiannis A; Mikhailidis DP
    Curr Vasc Pharmacol; 2010 Sep; 8(5):632-7. PubMed ID: 20507273
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 65. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
    ; Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
    J Am Coll Cardiol; 2016 Jul; 68(1):92-125. PubMed ID: 27046161
    [No Abstract]   [Full Text] [Related]  

  • 66. Combination therapy in dyslipidemia: where are we now?
    Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
    Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [ANMCO Position paper: Diagnostic and therapeutic pathways in patients with hypercholesterolemia and statin intolerance].
    Gulizia MM; Colivicchi F; Arca M; Abrignani MG; Perna GP; Mureddu GF; Nardi F; Riccio C;
    G Ital Cardiol (Rome); 2016 Jun; 17(6):447-55. PubMed ID: 27311087
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.
    Schreml J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1538-1548. PubMed ID: 28618994
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy.
    González CA; Rubio-Guerra AF; Pavía A; Redding FJ; Cervantes JL; Zacarías JL; Yza R; Carranza J; Fernández P; Morales E; Robles FJ; Leyva JL; Rodríguez L
    Clin Drug Investig; 2007; 27(5):333-7. PubMed ID: 17451281
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Are lower levels of low-density lipoprotein cholesterol beneficial? a review of recent data.
    Olsson AG
    Curr Atheroscler Rep; 2006 Sep; 8(5):382-9. PubMed ID: 16901408
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacogenomics of lipid-lowering therapies.
    Hu M; Tomlinson B
    Pharmacogenomics; 2013 Jun; 14(8):981-95. PubMed ID: 23746191
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
    Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
    N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.
    Nicholls S; Lincoff AM; Bays HE; Cho L; Grobbee DE; Kastelein JJ; Libby P; Moriarty PM; Plutzky J; Ray KK; Thompson PD; Sasiela W; Mason D; McCluskey J; Davey D; Wolski K; Nissen SE
    Am Heart J; 2021 May; 235():104-112. PubMed ID: 33470195
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
    Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
    Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?
    Cornier MA; Eckel RH
    Curr Atheroscler Rep; 2015; 17(2):475. PubMed ID: 25432858
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.
    Fleg JL; Mete M; Howard BV; Umans JG; Roman MJ; Ratner RE; Silverman A; Galloway JM; Henderson JA; Weir MR; Wilson C; Stylianou M; Howard WJ
    J Am Coll Cardiol; 2008 Dec; 52(25):2198-205. PubMed ID: 19095139
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management.
    Iatan I; Mancini GBJ; Yeoh E; Hegele RA
    Expert Rev Cardiovasc Ther; 2023 Jun; 21(6):423-435. PubMed ID: 37212306
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies.
    Cho L; Dent R; Stroes ESG; Stein EA; Sullivan D; Ruzza A; Flower A; Somaratne R; Rosenson RS
    Cardiovasc Drugs Ther; 2018 Aug; 32(4):365-372. PubMed ID: 30073585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.